Therapeutic apheresis in neurological disorders
2000; Wiley; Volume: 15; Issue: 1-2 Linguagem: Inglês
10.1002/(sici)1098-1101(2000)15
ISSN1098-1101
Autores Tópico(s)Multiple Sclerosis Research Studies
ResumoJournal of Clinical ApheresisVolume 15, Issue 1-2 p. 74-128 Therapeutic apheresis in neurological disorders Robert Weinstein M.D., Corresponding Author Robert Weinstein M.D. [email protected] Department of Medicine, Division of Hematology/Oncology and Transfusion Medicine, St. Elizabeth's Medical Center of Boston, Tufts University School of Medicine, Boston, MassachusettsHematology Section, St. Elizabeth's Medical Center of Boston, 736 Cambridge Street, MMR 3 HEM, Boston, MA 02135Search for more papers by this author Robert Weinstein M.D., Corresponding Author Robert Weinstein M.D. [email protected] Department of Medicine, Division of Hematology/Oncology and Transfusion Medicine, St. Elizabeth's Medical Center of Boston, Tufts University School of Medicine, Boston, MassachusettsHematology Section, St. Elizabeth's Medical Center of Boston, 736 Cambridge Street, MMR 3 HEM, Boston, MA 02135Search for more papers by this author First published: 29 March 2000 https://doi.org/10.1002/(SICI)1098-1101(2000)15:1/2 3.0.CO;2-OCitations: 56AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1aRopper AH. The Guillain-Barré syndrome. New Engl J Med 1992; 326: 1131–1136. 2a Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985; 35: 1096–1104. 3aKennedy RH, Danielson MA, Mulder DW, Kurland LT. Guillain-Barré syndrome: a 42-year epidemiological and clinical study. Mayo Clin Proc 1978; 53: 93–99. 4aHughes RAC. Plasma exchange in Guillain-Barré syndrome and related disorders. Transfus Sci 1993; 14: 3–8. 5aLöffel NB, Rossi LN, Mumenthaler M, Lutschg J, Ludin H-P. The Landry-Guillain-Barré syndrome: complications, prognosis and natural history in 123 cases. J Neurol Sci 1977; 33: 71–79. 6aArnason BGW. Acute inflammatory demyelinating polyradiculoneuropathies. In PJ Dyck, PK Thomas, EH Lambert, R Bunge, editors. Peripheral neuropathy, 2nd edition. Philadelphia: WB Saunders. 1984. p 2050–2100. 7aGracey DR, McMichan JC, Divertie MB Howard FM Jr. Respiratory failure in Guillain-Barré syndrome: a 6-year experience. Mayo Clin Proc 1982; 57: 742–746. 8aRavn H. The Landry-Guillain-Barré syndrome. A survey and a clinical report of 127 cases. Acta Neurol Scand 1967; 43(Suppl 30): 1–64. 9aOsterman PO, Fagius J, Safwenberg J, Wikstrom B. Early relapse of acute inflammatory polyradiculopathy after successful treatment with plasma exchange. Acta Neurol Scand 1988; 77: 273–277. 10aRopper AH, Albers JW, Addison R. Limited relapse in Guillain-Barré syndrome after plasma exchange. Arch Neurol 1988; 45: 314–315. 11aKleyweg RP, van der Meché FGA. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry 1991; 54: 957–960. 12aLandry O. Note sur la paralysie ascendante aiguë. Gaz Hebd Med Chir 1859; 6: 472–474. 13aGuillain G, Barré JA, Strohl A. Sur an syndrome de radiculo-névrite avec hyperalbuminose du liquide céphalo-rachidien sans réaction cellulaire: remarques sur les caracterès cliniques et graphiques des réflexes tendineux. Bull Mem Soc Med Hop Paris 1916; 40: 1462–1470. 14aFisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of opthalmoplegia, ataxia and areflexia). N Engl J Med 1956; 255: 57–65. 15aFeasby TE, Gilbert JJ, Brown WF, Bolton CF, Hahn AF, Koopman WF, Zochodne DW. An acute axonal form of Guillain-Barré polyneuropathy. Brain 1986; 109: 1115–1126. 16aRopper AH. Unusual clinical variants and signs of Guillain-Barré syndrome. Arch Neurol 1986; 43: 1150–1152. 17aMcKhann GM, Cornblath DR, Griffen JW, Ho TW, Li CY, Jiang Z, Wu HS, Zhaori G, Liu Y, Jou LP, et al. Acute motor axonal neuropathy: a frequent cause of flaccid paralysis in China. Ann Neurol 1933; 33: 333–342. 18aAsbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis: its role in pathogenesis. Medicine (Baltimore) 1969; 48: 173–215. 19aCook SD, Dowling PC, Murray MR Whitaker JN. Circulating demyelinating factors in acute idiopathic polyneuropatby. Arch Neurol 1971; 24: 136–144. 20aFeasby TE, Hahn AF, Gilbert JJ. Passive transfer studies in Guillain-Barré polyneuropathy. Neurology 1982; 32: 1159–1167. 21aSaida T, Saida K, Lisak RP, Brown MJ, Silverberg DH, Asbury AK. In vivo demyelinating activity of sera from patients with Guillain-Barré syndrome. Ann Neurol 1982; 11: 69–75. 22aSumner A, Said G, Idy I, Metral S. Syndrome de Guillain-Barré: Effets électrophysiologiques et morphologiques du sérum humain introduit dans l'espace endoneural du nerf sciatique du rat. Résultats préliminaires. Rev Neurol (Paris) 1982; 138: 17–24. 23aHarrison BM, Hansen LA, Pollard JD, McLeod JG. Demyelination induced by serum from patients with Guillain-Barré syndrome. Ann Neurol 1984; 15: 163–170. 24aHartung H-P, Toyka KV. T-cell and macrophage activation in experimental autoimmune neuritis and Guillain-Barré syndrome. Ann Neurol 1990; 27: S57–S63. 25aTaylor WA, Hughes RAC. T lymphocyte activation antigens in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J Neuroimmunol 1989; 24: 33–39. 26aHartung H-P, Reiners K, Schmidt B, Stoll G, Toyka KV. Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: Comparison with other neurological diseases of presumed immunopathogenesis. Ann Neurol 1991; 30: 48–53. 27aHartung H-P, Hughes RAC, Taylor WA, Heininger K, Reiners K, Toyka KV. T cell activation in Guillain-Barré syndrome and in MS: Elevated serum levels of soluble IL-2 receptors. Neurology 1990; 40: 215–218. 28aBansil S, Mithen FA, Singhal BS, Cook SD, Rohowsky-Kochan C. Elevated neopterin levels in Guillain-Barré syndrome. Further evidence of immune activation. Arch Neurol 1992; 49: 1277–1280. 29aHonavar M, Tharakan JKJ, Hughes RAC, Leibowitz S, Weiner JB. A clinicopathological study of the Guillain-Barré syndrome: nine cases and literature review. Brain 1991; 114: 1245–1269. 30aKoski CL, Humphrey R, Shin ML. Anti-peripheral nerve myelin antibody in patients with demyelinating neuropathy: quantitative and kinetic determination of serum antibody by complement component 1 fixation. Proc Natl Acad Sci USA 1985; 82: 905–909. 31aKoski CL, Gratz E, Sutherland J, Mayer RF. Clinical correlation with anti-peripheral-nerve myelin antibodies in Guillain-Barré syndrome. Ann Neurol 1986; 19: 573–577. 32aSanders ME, Koski CL, Robbins D, Shin ML, Frank MM, Joiner KA. Activated terminal complement in cerebrospinal fluid in Guillain-Barré syndrome and multiple sclerosis. J Immunol 1986; 136: 4456–4459. 33aKoski CL, Sanders ME, Swoveland PT, Lawley TJ, Shin ML, Frank MM, Joiner KA. Activation of terminal components of complement in ptients with Guillain-Barré syndrome and other demyelinating neuropathies. J Clin Invest 1987; 80: 1492–1497. 34aVriesendorp FJ, Mayer RF, Koski CL. Kinetics of anti-peripheral nerve myelin antibody in patients with Guillain-Barré syndrome treated and not treated with plasmapheresis. Arch Neurol 1991; 48: 858–861. 35aRudnicki S, Vriesendorp F, Koski CL, Mayer RF. Electrophysiologic studies in the Guillain-Barré syndrome: Effects of plasma exchange and antibody rebound. Muscle Nerve 1992; 15: 57–62. 36aIlyas AA, Willison HJ, Quarles RH, Jungalwala FB, Comblath DR, Trapp BD, Griffin DE, Griffin JW, McKhann GM. Serum antibodies to gangliosides in Guillain-Barré syndrome. Ann Neurol 1988; 23: 440–447. 37avan den Berg LH, Marrink J, de Jager AEJ, de Jong HJ, vaan Imhoff GW, Latov N, Sadiq SA. Anti GM1 antibodies in patients with Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1992; 55: 8–11. 38aGregson NA, Koblar S, Hughes RAC. Antibodies to gangliosides in Guillain-Barré syndrome: Specificity and relationship to clinical features. Q J Med 1993; 86: 111–117. 39aWillison HJ, Kennedy PGE. Gangliosides and bacterial toxins in Guillain-Barré syndrome. J Neuroimmunol 1993; 46: 105–112. 40avan der Meché FGA, Schmitz PIM and the Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. New Engl J Med 1992; 326: 1123–1129. 41aYuki N, Yoshino H, Sato S, Miyatake T. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 1990; 40: 1900–1902. 42aKornberg AJ, Pestronk A, Bieser K, Ho TW, McKhann GM, Wu HS, Jiang Z. The clinical correlates of high-titer IgG anti-GM1 antibodies. Ann Neurol 1994; 35: 234–237. 43aYuki N, Sato S, Tsuji S, Ohsawa T, Miyatake T. Frequent presence of anti-GQlb antibody in Fisher's Syndrome. Neurology 1993; 43: 414–417. 44aKuroki S, Saida T, Nukina M, Haruta T, Yoshioka M, Kobayashi Y, Nakanishi H. Campylobacter jejuni strains from patients with Guillain-Barré Syndrome belong mostly to Penner serogroup 19 and contain β-N-acety1g1ucosamine residues. Ann Neurol 1993; 33: 243–247. 45aYuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K, Handa S, Tadashi M. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med 1993; 178: 1771–1775. 46aHughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978; 2: 750–753. 47a Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993; 341: 586–590. 48aSingh NK, Gupta A. Do corticosteroids influence the disease course or mortality in Guillain-Barré syndrome? J Assoc Physicians India 1996; 44: 22–24. 49aMendell JR, Kissel JT, Kennedy MS, Sahenk Z, Grinvalsky HT, Pittman GL, Kyler RS, Roelofs RI, Whitaker JN, Bertorini TE. Plasma exchange and prednisone in Guillain-Barré syndrome: A controlled randomized trial. Neurology 1985; 35: 1551–1555. 50aBrettle RP, Gross MLP, Legg NJ, Lockwood M, Pallis C. Treatment of acute polyneuropathy by plasma exchange. Lancet 1978; 2: 1100. 51aSchooneman F, Janot C, Streiff F, Gerard A, Dureux JB, Canton P, Roche G, Aubrun P. Plasma exchange in Guillain-Barré syndrome: ten cases. Plasma Ther 1981; 2: 117–121. 52aValbonesi M, Garelli S, Mosconi L, Zerbi D, Celano I. Plasma exchange as a therapy for Guillain-Barré syndrome with immune complexes. Vox Sang 1981; 41: 74–78. 53ade Jager AEJ, The TH Smit Sibinga CTS, Das PC. Plasma exchange in the Guillain-Barré syndrome. Br Med J 1981; 283: 794–795. 54aRumpl E, Mayr U, Gerstenbrand F, Hackl JM, Rosmanith P, Aichner F. Treatment of Guillain-Barré syndrome by plasma exchange. J Neurol 1981; 225: 207–217. 55aGreenwood RJ, Hughes RAC, Bowden AN, Gordon NS, Millac P, Newsom-Davis J, Aslan S, Chadwick DW, McLellan DL, Stott RB, Armitage P. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984; 1: 877–879. 56aOsterman PO, Lundemo G, Pirskanen R, Fagius J, Pihlstedt P, Siden A, Safwenberg J. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984; 2: 1296–1299. 57a French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987; 22: 753–761. 58a French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Plasma exchange in Guillain-Barré syndrome: one-year follow-up. Ann Neurol 1992; 32: 94–97. 59a French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 1997; 41: 298–306. 60aDau PC, Lindstrom JM, Cassel CK Denys EH, Shev EE, Spitler LE. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. New Engl J Med 1977; 297: 1134–1140. 61aDyck PJ, Daube L, O'Brien P, Pineda A, Low PA, Windebank AJ, Swanson C. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. New Engl J Med 1986; 314: 461–465. 62aDyck PJ, Low PA, Windebank AJ, Jaradeh SS, Gosselin S, Bourque P, Smith BE, Kratz KM, Karnes JL, Evans BA, Pineda AA, O'Brien PC, Kyle RA. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. New Engl J Med 1991; 325: 1482–1486. 63aKleyweg RP, van der Meché FGA, Meulstee J. Treatment of Guillain-Barré syndrome with high-dose gammaglobulin. Neurology 1988; 38: 1639–1641. 64aJackson MC, Godwin-Austen RB, Whiteley AM. High-dose intravenous immunoglobulin in the treatment of Guillain-Barré syndrome: a preliminary open study. J Neurol 1993; 240: 51–53. 65aBleck TP: IVIg for GBS. Potential problems in the alphabet soup. Neurology 1993; 43: 857–858. 66aWeinstein, R. Treatment of Guillain-Barré syndrome. Listening carefully to the music before jumping on the bandwagon. Transfus Sci 15: 490–495, 1994. 67aMcKhann GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS, Quasker SA and the Guillain-Barré Syndrome Study Group. Plasmapheresis and Guillain-Barré syndrome: Analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 1988; 23: 347–353. 68aGreuner G, Bosch EP, Strauss RG Glugman M, Kimura J. Prediction of early beneficial response to plasma exchange in Guillain-Barré syndrome. Arch Neurol 1987; 44: 295–298. 69aCastro LHM, Ropper AH. Human immune globulin infusion in Guillain-Barré syndrome: Worsening during and after treatment. Neurology 1993; 43: 1034–1036. 70aIrani DN, Cornblath DR, Chaudhry V, Borel C, Hanley DF. Relapse in Guillain-Barré syndrome after treatment with human immune globulin. Neurology 1993; 43: 872–875. 71a Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997; 349: 225–230. 1bAustin JH. Recurrent polyneuropathies and their corticosteroid treatment. With five-year observations of a placebo-controlled case treated with corticotrophin, cortisone and prednisone. Brain 1958; 81: 157–192. 2bThomas PK, Lascelles RG, Hallpike JF, Hewer RL. Recurrent and chronic relapsing Guillain-Barré polyneuritis. Brain 1969; 92: 589–606. 3bDyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975; 50: 621–637. 4bPrineas JW, McLeod JG. Chronic relapsing polyneuritis. J Neurol Sci 1976; 27: 427–458. 5bOh SJ. Subacute demyelinating polyneuropathy responding to corticosteroid treatment. Arch Neurol 1978; 35: 509–516. 6bDalakas MC, Engel WK. Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann Neurol 1981; 9(Suppl): 134–145. 7bDyck PJ, O'Brien PC, Oviatt KF, Dinapoli RP, Daube JR, Bartleson JD, Mokri B, Swift T, Low PA, Windebank AJ. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982; 11: 136–141. 8bBarohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course and recommendations for diagnostic criteria. Arch Neurol 1989; 46: 878–884. 9bMcCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 1987; 110: 1617–1630. 10bCornblath DR, Asbury AK, Albers JW, Feasby TE, Hahn AF, McLeod JG, Mendell JR, Parry GJ, Pollard JD, Thomas PK. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an ad hoc subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991; 41: 617–618, 11bBromberg MB, Feldman EL, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy: Comparison of patients with and without an associated monoclonal gammopathy. Neurology 1992; 42: 1157–1163. 12bSimmons Z, Albers JW, Bromberg MB, Feldman EL. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: Comparison of patients without and with monoclonal gammopathy. Neurology 1993; 43: 2202–2209. 13bGorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: Clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997; 48: 321–328. 14bAlbers JW, Kelly JJ Jr. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve 1989; 12: 435–451. 15bBromberg MB. Comparison of electrodiagnostic criteria for primary demyelination in chronic polyneuropathy. Muscle Nerve 1991; 14: 968–976. 16bHeininger K, Liebert UG, Toyka KV, Haneveld FT, Schwendemann G, Kolb-Bachofen V, Ross HG, Cleveland S, Besinger UA, Gibbels E. Chronic inflammatory polyneuropathy. Reduction of nerve conduction velocities in monkeys by systemic passive transfer of immunoglobulin G. J Neurol Sci 1984; 66: 1–14. 17bSaida T, Saida K, Dorfman SH, Silberberg DH, Sumner AJ, Manning MC, Lisak RP, Brown MJ. Experimental allergic neuritis induced by sensitization with galactocerebroside. Science 1979; 204: 1103–1106 18bSaida K, Sumner AJ, Saida T, Brown MJ, Silberberg DH. Antiserum-mediated demyelination: relationship between remyelination and functional recovery. Ann Neurol 1980; 8: 12–24. 19bStoll G, Schwendemann G, Heininger K, Kohne W, Hartung HP, Seitz R, Toyka KV. Relation of clinical, serological, morphological, and electrophysiological findings in galactocerebroside-induced experimental allergic neuritis. J Neurol Neurosurg Psychiatry 1986; 49: 258–264. 20bDalakas MC, Engel WK. Immunoglobulin and complement deposits in peripheral nerves of patients with chronic relapsing polyneuropathy. Arch Neurol 1980; 37: 637–640. 21bDalakas M, Houff S, Engel WK, Madden DL, Sever JL. CSF "monoclonal" bands in chronic relapsing polyneuropathy. Neurology 1980; 30: 864–867. 22bLatov N, Gross RB, Kastelman J, Flanagan T, Lamme S, Alkaitis DA, Olarte MR, Sherman WH, Chess L, Penn AS. Complement-fixing antiperipheral nerve myelin antibodies in patients with inflammatory polyneuritis and with polyneuropathy and paraproteinemia. Neurology 1981; 31: 1530–1534. 23bKoski CL, Humphrey R, Shin ML. Anti-peripheral nerve myelin antibody in patients with demyelinating neuropathy: quantitative and kinetic determination of serum antibody by complement component 1 fixation. Proc Natl Acad Sci USA 1985; 82: 905–909. 24bKhalili-Shirazi A, Atkinson P, Gregson N, Hughes RA. Antibody responses to P0 and P2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J Neuroimmunol 1993; 46: 245–251. 25bConnolly AM, Pestronk A, Trotter JL, Feldman EL, Cornblath DR, Olney RK. High-titer selective serum anti-beta-tubulin antibodies in chronic inflammatory demyelinating polyneuropathy. Neurology 1993; 43: 557–562. 26bIlyas AA, Mithen FA, Dalakas MC, Chen ZW, Cook SD. Antibodies to acidic glycolipids in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 1992; 107: 111–121. 27bSimone IL, Annunziata P, Maimone D, Liguori M, Leante R, Livrea P. Serum and CSF anti-GM1 antibodies in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 1993; 114: 49–55. 28bvan Schaik IN, Vermeulen M, van Doorn PA, Brand A. Anti GM1 antibodies in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) treated with intravenous immunoglobulin (IVIg). J Neuroimmunol 1994; 54: 109–115. 29bVrethem M, Skogh T, Berlin G, Holmgren H, Ernerudh J. Antibodies to peripheral nerve myelin may occur without clinical neuropathy in healthy persons. J Neuroimmunol 1991; 32: 219–222. 30bPentland B, Adams GGW, Mawdsley C. Chronic idiopathic polyneuropathy treated with azathioprine. J Neurol Neurosurg Psychiatry 1982; 45: 866–869. 31bMahattanakul W, Crawford TO, Griffin JW, Goldstein JM, Cornblath DR. Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A. J Neurol Neurosurg Psychiatry 1996; 60: 186–187. 32bDyck PJ, O'Brien PC, Swanson C, Low P, Daube J. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology 1985; 35: 1173–1176. 33bSaida T, Saida K, Silberberg DH, Brown MJ. Transfer of demyelination by intraneural injection of experimental allergic neuritis serum. Nature 1978; 272: 639–641. 34bDau PC, Lindstrom JM, Cassel CK, Denys EH, Shev EE, Spitler LE. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med 1977; 297: 1134–1140. 35bServer AC, Lefkowith J, Braine H, McKhann GM. Treatment of chronic relapsing inflammatory polyradiculoneuropathy by plasma exchange. Ann Neurol 1979; 6: 258–261. 36bLevy RL, Newkirk R, Ochoa J. Treating chronic relapsing Guillain-Barré syndrome by plasma exchange. Lancet 1979; 2: 259–260. 37bFowler H, Vulpe M, Marks G, Egolf C, Dau PC. Recovery from chronic progressive polyneuropathy after treatment with plasma exchange and cyclophosphamide. Lancet 1979; 2: 1193. 38bGross MLP, Thomas PK. The treatment of chronic relapsing and chronic progressive idiopathic inflammatory polyneuropathy by plasma exchange. J Neurol Sci 1981; 52: 69–78. 39bToyka KV, Augspach R, Wietholter H, Besinger UA, Haneveld F, Liebert UG, Heininger K, Schwendemann G, Reiners K, Grabensee B. Plasma exchange in chronic inflammatory polyneuropathy: evidence suggestive of a pathogenic humoral factor. Muscle Nerve 1982; 5: 479–484. 40bConnor RK, Ziter FA, Anstall HB. Childhood chronic relapsing polyneuropathy: dramatic improvement following plasmapheresis. J Clin Apheresis 1982; 1: 46–49. 41bvan Nunen SA, Gatenby PA, Pollard JD Deacon M, Clancy RL. Specificity of plasmapheresis in the treatment of chronic relapsing polyneuropathy. Aust NZ J Med 1982; 12: 81–84. 42bPollard JD, McLeod JG, Gatenby P, Kronenberg H. Prediction of response to plasma exchange in chronic relapsing polyneuropathy. J Neurol Sci 1983; 58: 269–287. 43bDyck PJ, Daube J, O'Brien P, Pineda A, Low PA, Windebank AJ, Swanson C. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986; 314: 461–465. 44bHahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V, Shumak K, Vandervoort MK, Feasby TE. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996; 119: 1055–1066. 45bMaas AIR, Busch HFM, van der Heul C. Plasma infusion and plasma exchange in chronic idiopathic polyneuropathy. N Engl J Med 1981; 305: 344. 46bVermeulen M, van der Meché FG, Speelman JD, Weber A, Busch HF. Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. J Neurol Sci 1985; 70: 317–326. 47bvan der Meché FG, Vermeulen M, Busch HF. Chronic inflammatory demyelinating polyneuropathy. Conduction failure before and during immunoglobulin or plasma therapy. Brain 1989; 112: 1563–1571. 48bFaed JM, Day B, Pollock M, Taylor PK, Nakuda H, Hammond-Tooke GD. High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Neurology 1989; 39: 422–425. 49bCornblath DR, Chaudhry V, Griffin JW. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Ann Neurol 1991; 30: 104–106. 50bvan Doorn PA, Brand A, Strengers PFW, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled, crossover study. Neurology 1990; 40: 209–212. 51bvan Doorn PA, Vermeulen M, Brand A, Mulder PG, Busch HF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neurol 1991; 48: 217–220. 52bVermeulen M, van Doorn PA, Brand A, Strengers PFW, Jennekens FGI, Busch HFM. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993; 56: 36–39. 53bHahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996; 119: 1067–1077. 54bDyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, Windebank AJ, Karnes JL, O'Brien PC. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994; 36: 838–845. 55bChoudhary PP, Hughes RAC. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. Q J Med 1995; 88: 493–502. 56bvan Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604–607. 57b Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985; 35: 1096–1104. 1cLang B, Newsom-Davis J, Wray D, Vincent A, Murray N. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 1981; 2: 224–226. 2cNewsom-Davis J, Murray N, Wray D, Lang B, Prior C, Gwilt M, Vincent A. Lambert-Eaton myasthenic syndrome: electrophysiological evidence for a humoral factor. Muscle Nerve 1982; 5: S17–S20. 3cLeys K, Lang B, Johnston I, Newsom-Davis J. Calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Ann Neurol 1991; 29: 307–314. 4cMaselli RA. Pathophysiology of myasthenia gravis and Lambert-Eaton syndrome. Neurol Clin N Am 1994; 12: 285–303. 5cLennon VA, Kryzer TJ, Griesmann GE, O'Suilleabilain PE, Windebank AJ, Woppmann A, Miljanich GP, Lambert EH. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995; 332: 1467–1474. 6cSanders DB. Lambert-Eaton myasthenic syndrome: Clinical diagnosis, immune-mediated mechanisms, and update on therapies. Ann Neurol 1995; 37: S63–S73. 7cLang B, Waterman S, Pinto A, Jones D, Moss F, Boot J, Brust P, Williams M, Stauderman K, Harpold M, Motomura M, Moll JW, Vincent A, Newsom-Davis J. The role of autoantibodies in Lambert-Eaton myasthenic syndrome. Ann NY Acad Sci 1998; 841: 596–605. 8cMcEvoy KM. Diagnosis and treatment of Lambert-Eaton myasthenic syndrome. Neurol Clin N Am 1994; 12: 387–399. 9cAnderson HJ, Churchill-Davidson HC, Richardson AT. Bronchial neoplasm with myasthenia. Prolonged apea after administration of succinylcholine. Lancet 1953; 2: 1291–1293. 10cLambert EH, Eaton LM, Rooke ED. Defect of neuromuscular conduction associated with malignant neoplasms. Am J Physiol 1956; 187: 612–613. 11cElmqvist D, Lambert EH. Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma. Mayo Clin Proc 1968; 43: 689–713. 12cGutmann L, Crosby TW, Takamori M, Martin JD. The Eaton-Lambert syndrome and autoimmune disorders. Am J Med 1972; 53: 354–356. 13cStreib EW, Rothner DA. Eaton-Lambert myasthenic syndrome: long-term treatment of three patients with prednisone. Ann Neurol 1980; 8: 121–122. 14cFukunaga H, Engel AG, Osame M, Lambert EH. Paucity and
Referência(s)